10 Covidien PLC Analyst Ratings, Earnings, Dividends and Insider Trades | $COV | NYSE:COV | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Covidien PLC Company Profile (NYSE:COV) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Covidien PLC (NYSE:COV) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 2 Hold Rating(s), 12 Buy Rating(s), 1 Strong Buy Rating(s)Consensus Rating:Buy (Score: 2.93)Consensus Price Target: $75.44 (5.58% upside) Analysts' Ratings History for Covidien PLC (NYSE:COV) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/6/2014BarclaysBoost Price TargetOverweight$77.00 -> $82.00View 2/26/2014CRT CapitalInitiated CoverageBuy$82.00View 1/27/2014Deutsche BankBoost Price TargetBuy$75.00 -> $77.00View 1/27/2014RBC CapitalBoost Price Target$70.00 -> $71.00View 1/27/2014Leerink SwannBoost Price Target$78.00 -> $80.00View 1/20/2014Jefferies GroupBoost Price Target$74.00 -> $80.00View 1/14/2014RBC CapitalBoost Price TargetSector Perform$65.00 -> $70.00View 12/13/2013JMP SecuritiesInitiated CoverageOutperform$76.00View 12/5/2013BarclaysBoost Price TargetOverweight$72.00 -> $77.00View 12/5/2013Benchmark Co.Initiated CoverageBuy$82.00View 11/27/2013Leerink SwannBoost Price Target$76.00View 11/26/2013Needham & CompanyReiterated RatingBuy$74.00View 11/26/2013Raymond JamesBoost Price TargetHold$72.00 -> $77.00View 11/11/2013ZacksReiterated RatingNeutral -> Neutral$67.00View 11/8/2013Needham & CompanyBoost Price TargetBuy$69.00 -> $74.00View 9/16/2013Needham & CompanyReiterated RatingBuy$69.00View 9/16/2013Jefferies GroupLower Price TargetBuy$72.00 -> $68.00View 9/11/2013Goldman SachsUpgradeNeutral -> BuyView 9/4/2013Needham & CompanyInitiated CoverageBuy$69.00View 8/14/2013ZacksUpgradeUnderperform -> Neutral$67.00View 8/5/2013Deutsche BankBoost Price Target$68.00 -> $70.00View 8/2/2013Raymond JamesBoost Price TargetStrong$65.00 -> $72.00View 8/2/2013JPMorgan Chase & Co.Boost Price TargetOverweight$63.00 -> $71.00View 8/2/2013Jefferies GroupBoost Price TargetBuy$62.00 -> $72.00View 8/2/2013BarclaysReiterated RatingOverweight$72.00 -> $67.00View 7/3/2013BarclaysLower Price TargetBuy$74.00 -> $67.00View 7/1/2013Jefferies GroupLower Price TargetBuy$75.00 -> $62.00View 7/1/2013Deutsche BankLower Price TargetBuy$74.00 -> $68.00View 6/28/2013BMO Capital MarketsReiterated RatingOutperform$72.00 -> $64.00View 6/19/2013Goldman SachsReiterated RatingNeutralView 6/7/2013BarclaysReiterated RatingOverweight$74.00View 5/29/2013Brean CapitalReiterated RatingBuy$72.00View 5/29/2013MizuhoBoost Price TargetBuy$70.00 -> $76.00View 5/6/2013Brean CapitalBoost Price TargetBuy$70.00 -> $72.00View 5/6/2013BMO Capital MarketsLower Price TargetOutperform$75.00 -> $72.00View 5/6/2013BarclaysReiterated RatingOverweight$70.00 -> $74.00View 4/30/2013RBC CapitalLower Price TargetSector Perform$69.00 -> $67.00View 4/30/2013JPMorgan Chase & Co.Lower Price TargetOverweight$71.00 -> $69.00View 4/29/2013TheStreetReiterated RatingBuyView 4/12/2013Deutsche BankBoost Price TargetBuy$70.00 -> $74.00View 3/27/2013Jefferies GroupBoost Price TargetBuy$66.00 -> $75.00View 3/27/2013Jefferies GroupSet Price TargetBuy$66.00 -> $75.00View 3/22/2013S&P Equity ResearchBoost Price TargetStrong-Buy$72.00 -> $76.00View 3/20/2013RBC CapitalBoost Price TargetSector Perform$66.00 -> $69.00View 3/6/2013Atlantic SecuritiesInitiated CoverageOverweight$75.00View 3/5/2013TheStreetReiterated RatingBuyView 2/15/2013TheStreetReiterated RatingBuyView 2/12/2013BMO Capital MarketsBoost Price TargetOutperform$68.00 -> $72.00View 2/4/2013RBC CapitalBoost Price TargetSector Perform$59.00 -> $66.00View 1/28/2013Brean CapitalBoost Price TargetBuy$66.00 -> $70.00View 1/28/2013BarclaysBoost Price TargetOverweight$64.00 -> $70.00View 1/28/2013Goldman SachsReiterated RatingNeutral$63.00 -> $66.00View 1/28/2013Citigroup Inc.Reiterated RatingBuy$64.00 -> $71.00View 1/28/2013MizuhoBoost Price TargetBuy$65.00 -> $70.00View 1/8/2013TheStreetReiterated RatingBuyView 1/4/2013Deutsche BankBoost Price TargetBuy$64.00 -> $70.00View 1/2/2013Citigroup Inc.Reiterated RatingBuy$64.00View 12/31/2012Goldman SachsReiterated RatingNeutral$62.00 -> $63.00View 11/20/2012Brean CapitalInitiated CoverageBuy$66.00View 11/19/2012Stifel NicolausInitiated CoverageHoldView 9/14/2012Citigroup Inc.Boost Price TargetBuy$64.00 -> $68.00View 9/14/2012Jefferies GroupReiterated RatingBuy$61.00 -> $66.00View 9/14/2012MizuhoBoost Price TargetBuy$62.00 -> $64.00View 9/12/2012BarclaysReiterated RatingOverweightView 8/23/2012BarclaysReiterated RatingOverweightView 8/23/2012Jefferies GroupReiterated RatingBuyView 7/27/2012MizuhoLower Price TargetBuy$64.00 -> $61.00View 5/8/2012BarclaysBoost Price TargetOverweight$57.00 -> $62.00View 5/8/2012JPMorgan Chase & Co.Boost Price Target$59.00 -> $64.00View 5/7/2012MizuhoBoost Price TargetBuy$61.00 -> $64.00View 5/1/2012Deutsche BankBoost Price TargetBuy$59.00 -> $62.00View 4/30/2012Piper JaffrayBoost Price TargetOverweight$60.00 -> $64.00View 4/30/2012Bank of AmericaBoost Price TargetBuy$61.00 -> $64.00View 4/30/2012Morgan StanleyBoost Price Target$56.00 -> $61.00View 4/30/2012Citigroup Inc.Boost Price Target$60.00 -> $64.00View 4/25/2012Raymond JamesInitiated CoverageStrong-BuyView 3/14/2012Jefferies GroupReiterated RatingBuy$61.00View 3/12/2012William BlairInitiated CoverageOutperformView (Data available from 3/7/2012 forward) Earnings History for Covidien PLC (NYSE:COV)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare1/24/2014Q114$0.94$1.00$2.61 billion$2.64 billionViewListenView 11/8/2013Q413$0.90$0.91$2.56 billion$2.56 billionViewListenView 8/1/2013Q3 2013$0.89$0.85$2.58 billion$2.58 billionViewListenView 4/26/2013Q2 2013$1.09$1.12$3.12 billion$3.10 billionViewListenView 1/25/2013Q1 2013$1.06$1.10$3.00 billion$3.06 billionViewListenView 11/9/2012Q412$1.00$1.02$2.98 billion$3.00 billionViewN/AView 7/26/2012$1.06$1.07ViewN/AView 4/27/2012$1.03$1.05ViewN/AView 1/26/2012$1.03$1.13ViewN/AView 11/15/2011$1.05$1.08ViewN/AView 7/26/2011$0.94$1.01ViewN/AView 4/21/2011$0.89$0.93ViewN/AView 2/1/2011$0.81$0.95ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Covidien PLC (NYSE:COV)AnnouncedPeriodAmountEx-Dividend DateRecord DatePayable DateShare1/16/2014quarterly$0.321/24/20141/28/20142/20/2014 9/19/2013quarterly$0.3210/8/201310/10/201311/5/2013 7/17/2013quarterly$0.267/26/20137/30/20138/15/2013 3/21/2013quarterly$0.264/2/20134/4/20135/3/2013 12/4/2012quarterly$0.2612/14/201212/27/2012 (Data available from 1/1/2013 forward) Insider Trading History for Covidien PLC (NYSE:COV)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare2/28/2014Jose AlmeidaInsiderSell50,000$72.00$3,600,000.00View 2/13/2014Richard Brown, Jr.VPSell4,000$71.00$284,000.00View 2/11/2014Brian Douglas KingVPSell17,946$70.00$1,256,220.00View 2/11/2014Bryan HansonSVPSell32,480$69.97$2,272,625.60View 1/29/2014Coleman Lannum IIIVPSell13,787$69.23$954,474.01View 1/24/2014Richard Brown, Jr.VPSell4,000$70.00$280,000.00View (Data available from 1/1/2013 forward) About Covidien PLC Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. It operates its businesses through three segments: Medical Devices, which includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products; Pharmaceuticals, which includes the development, manufacture and distribution of specialty pharmaceuticals and active pharmaceutical ingredients, and Medical Supplies, SharpSafety products and original equipment manufacturer products. In January 2013, the Company acquired CV Ingenuity. In July 2013, the Company completed the separation of its Pharmaceuticals business, which is held by Mallinckrodt plc. Headlines: (3/6) Covidien to Present at Barclays Global Healthcare Conference 2014 (3/6) Covidien Next-Gen Ventilator Gets CE Mark (3/6) Covidien Next-Gen Ventilator Gets CE Mark - Analyst Blog (3/3) Covidien Announces CE Mark Approval for Puritan Bennett™ 980 Ventilator (3/3) Weekly 52-Week Highs Highlight: COV, EQT, XLNX, TEVA (2/24) Covidien to Present at Raymond James 35th Annual Institutional Investors Conference (2/27) Covidien Completes Acquisition of Given Imaging (2/18) Covidien to Present at Upcoming Investor Conferences Industry, Sector and Symbol: Sector: Healthcare Industry: Health Care Equipment & Supplies Sub-Industry: Health Care Equipment Exchange: NYSE Symbol: COV CUSIP: G2554F11 Key Metrics: Previous Close: $71.4050 Day Moving Average: $69.4488200 Day Moving Average: $65.5371 P/E Ratio: 20.74P/E Growth: 1.87Market Cap: $32.206BCurrent Quarter EPS Consensus Estimate: $4.01 EPS Additional Links: View COV on Google FinanceView COV on Yahoo FinanceView COV's Company Profile on ReutersSearch for Covidien PLC on Google Covidien PLC (NYSE:COV) Chart for Friday, March, 7, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.